Results 1 to 10 of about 50,432 (266)
Canadian Medical Association Journal, 2007 In their recent systematic review, Suzanne Ligthart and associates compared analyses of the cost-effectiveness of drug-eluting stents.[1][1] They found that in most studies in which an incremental cost-effectiveness ratio greater than $50 000 per quality-adjusted life-year was calculated the ...
Tangri N, Falcone El
+16 more sources
BMJ, 2006 Last week an expert panel of the US Food and Drug Administration (FDA) recommended that the FDA should issue warnings to doctors and patients about drug eluting coronary stents. The safety of such stents is unclear except in low risk patients. Furthermore, patients with drug eluting stents should take antiplatelet therapy for at least one year after ...
Gershlick, AH, Richardson, G
+13 more sources
Semin Intervent Radiol, 2022 AbstractEndovascular revascularization strategies have advanced tremendously over the years and are now often considered first line for treatment of peripheral arterial disease. Drug-eluting stents (DESs) have been developed as one of the tools to overcome the limitations of elastic recoil and neointimal hyperplasia observed with balloon angioplasty ...
Velagapudi C, Madassery S.
europepmc +3 more sources
A novel glycyrrhizin acid-coated stent reduces neointimal formation in a rabbit iliac artery model
Frontiers in Pharmacology, 2023 Introduction: Most drug-eluting stents (DESs) inhibit intimal hyperplasia but impair re-endothelialization. This study aimed to evaluate in vivo strut coverage and neointimal growth in a new glycyrrhizin acid (GA)-eluting stent.Methods: New Zealand White
Shuai Teng +6 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2021 Background and Objectives: The second-generation drug-eluting stents have been used to treat chronic total occlusion lesion. However, there is limited evidence of the clinical outcomes that whether the second-generation drug-eluting stents is superior to
Xuan Qiao +5 more
doaj +1 more source
Drug eluting stents in 2005 [PDF]
Heart, 2005 In the last 3–5 years there has been a major shift in the management of symptomatic, obstructive coronary artery disease, with a move from predominantly surgical to increasingly a percutaneous approach. The perceived benefits of percutaneous coronary intervention (PCI) include patient convenience, ease of service expansion, and the fact that more ...
Anthony Gershlick
openalex +4 more sources
Drug-eluting stent thrombosis [PDF]
Therapeutic Advances in Cardiovascular Disease, 2009 Stent thrombosis is a rare complication following stent implantation; if it occurs, however, it is associated with a high morbidity and mortality. Despite reduced rates of restenosis, drug-eluting stents (DES) have not reduced the incidence of stent thrombosis as compared with bare-metal stents (BMS).
Stähli, B E, Camici, G G, Tanner, F C
openaire +3 more sources
Stent thrombosis and drug-eluting stents [PDF]
Journal of Cardiology, 2011 Coronary stents have been used for the treatment of patients with coronary artery disease (CAD), and significantly improved procedural safety and are associated with a lower rate of restenosis compared with balloon angioplasty alone. Drug-eluting stents (DES) have been dominant for the treatment of CAD with efficacy in significantly reducing both ...
Takafumi Hiro +2 more
openaire +3 more sources
Drug-eluting stent in diabetes [PDF]
Sao Paulo Medical Journal, 2007 Long-term evaluation of cardiovascular risk among diabetic patients has shown that the incidence of death due to myocardial infarction among these patients is 20%, whereas among nondiabetic patients it is only 3.5%. Such observations haveled to classifying diabetes as a risk that is equivalent to establi shed coronary artery disease.
Walter J. Gomes +4 more
openaire +4 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background Premature discontinuation of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention is related to higher short‐term risks of adverse outcomes. Whether these risks persist in the long‐term is uncertain. Methods and Results We
Scott Kinlay +11 more
doaj +1 more source